Iclaprim

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review

Abstract

Iclaprim (previously known as AR-100 and Ro 48-2622) is a new member of the diaminopyrimidine class of antimicrobials, to which trimethoprim also belongs. As with trimethoprim, iclaprim is an inhibitor of bacterial dihydrofolate reductase (DHFR), an enzyme in the folate synthesis pathway. The two potential advantages of iclaprim compared with trimethoprim are an increased affinity for bacterial DHFR, particularly in Gram-positive bacteria, and activity against trimethoprim-resistant organisms. Iclaprim is therefore a potentially interesting new agent for the treatment of multiresistant Gram-positive infections.

Original languageEnglish
Title of host publicationKucers the Use of Antibiotics
Subtitle of host publicationA Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs
EditorsM. Lindsay Grayson
Place of PublicationBoca Raton FL USA
PublisherCRC Press
Pages1775-1783
Number of pages9
Edition7th
ISBN (Electronic)9781498747967
ISBN (Print)9781498747950
Publication statusPublished - 2 Oct 2017

Cite this

Stewardson, A., & Lindsay Grayson, M. (2017). Iclaprim. In M. L. Grayson (Ed.), Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs (7th ed., pp. 1775-1783). CRC Press.